Advertisement
Document › Details
Sofinnova Partners. (10/19/21). "Press Release: Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-stage Healthcare VC Fund in Europe". Paris.
Region | Europe | |
Organisation | Sofinnova Partners SAS | |
Group | Sofinnova (Group) | |
Organisation 2 | Clifford Chance, Paris | |
Group | Clifford Chance (Group) | |
Product | fund, biotech / life sciences | |
Product 2 | LIFE SCIENCES | |
Person | Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997) | |
Person 2 | Richter, Henrijette (Sofinnova Partners 201509 before Novo Group 201304 at Novo Seeds) | |
European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the close of its latest early-stage healthcare venture capital fund, Sofinnova Capital X, oversubscribed at €472 ($548) million. This brings the total amount the VC has raised to €1 billion in the last 12 months across its multi-fund platform, and the total AUM to over €2.5 billion. Capital X, the 10th iteration of Sofinnova Partners’ flagship fund, is the largest healthcare fund dedicated to early-stage investments and company creation in Europe.
Sofinnova Capital X will invest in the most promising biopharmaceutical and medical device start-ups that address pressing unmet clinical needs and aim to transform patients’ lives. In keeping with the current strategy, the team will source and create value across a portfolio of groundbreaking innovations in healthcare, supporting entrepreneurs globally in the creation and growth of their companies.
Capital X was successfully raised with institutional investors including pension funds, insurance companies, foundations, endowments, corporate investors, and prominent family offices from across Europe, Asia, and North America. The Fund welcomed back existing investors and attracted new blue chip limited partners, reflecting sustained confidence in the firm’s capacity to generate strong financial returns.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said: “The close of Capital X, significantly oversubscribed and raised in record time, comes at a pivotal moment as the importance of healthcare innovation has become exceedingly clear to all. The fact we have been able to raise €1 billion across our platform over the past 12 months is a tribute to our investors and their conviction in our ability to bolster our leading position in Europe.”
Henrijette Richter, Managing Partner of Sofinnova Partners, said: “We are thrilled to have raised the largest fund dedicated to early-stage healthcare investments in Europe. This is an important milestone for Sofinnova Partners. Capital X will allow us to leverage over 30 years of cumulative experience perfecting this strategy. We now have more capital than ever to support leading entrepreneurs as they launch new companies to develop groundbreaking therapies that have the potential to change peoples’ lives.”
Clifford Chance acted as legal counsel and Triago as placement agent.
###
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
Media Contacts:
Bommy Lee
Head of Communications, Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Rafaella Casula rafaella.casula@havaspr.com
+39 (0) 345 3780834
Record changed: 2023-06-05 |
Advertisement
More documents for Sofinnova (Group)
- [1] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
- [2] Biotimus SAS. (2/20/24). "Press Release: Ex-Google DeepMind and Owkin Scientists Team up to Create Bioptimus to Build the First Universal AI Foundation Model for Biology"....
- [3] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
- [4] Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich....
- [5] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris....
- [6] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners and Gustave Roussy Forge Strategic Alliance to Boost Oncology Startup Acceleration in France". Paris....
- [7] Sofinnova Partners. (12/5/23). "Press Release: Sofinnova Partners Unveils Sofinnova.AI – a Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment practice". Paris....
- [8] GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris....
- [9] T-Therapeutics Ltd.. (11/15/23). "Press Release: T-Therapeutics Raises £48 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment". Cambridge....
- [10] Nuage Therapeutics. (6/20/23). "Press Release: Nuage Therapeutics Raises €12M in Seed Financing Led by Sofinnova Partners and Asabys". Barcelona....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top